The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Update on the treatment of Pseudomonas aeruginosa pneumonia
Abstract
Pseudomonas aeruginosa is an important cause of nosocomial pneumonia associated with a high morbidity and mortality rate. This bacterium expresses a variety of factors that confer resistance to a broad array of antimicrobial agents. Empirical antibiotic therapy is often inadequate because cultures from initial specimens grow strains that are resistant to initial antibiotics. Surveillance data, hospital antibiogram and individualization of regimens based on prior antibiotic use may reduce the risk of inadequate therapy. The use of combination therapies for P. aeruginosa pneumonia has been a long-advocated practice, but the potential increased value of combination therapy over monotherapy remains controversial. Doripenem and biapenem are new carbapenems that have excellent activity against P. aeruginosa; however, they lack activity against strains that express resistance to the currently available carbapenems. The polymyxins remain the most consistently effective agents against multidrug-resistant P. aeruginosa. Strains that are panantibiotic-resistant are rare, but their incidence is increasing. Antibiotic combinations that yield some degree of susceptibility in vitro are the recourse, although the efficacy of these regimens has yet to be established in clinical studies. Experimental polypeptides may provide a new therapeutic approach. Among these, the anti-PcrV immunoglobulin G antibody that blocks the type III secretion system-mediated virulence of P. aeruginosa has recently entered Phase I/II clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Cited by
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
The antibacterial properties of phenolic isomers, carvacrol and thymol
Kachur, K., & Suntres, Z. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1675585 · Cited by 558
Nseir, S., Blazejewski, C., Lubret, R., Wallet, F., Courcol, R., & Durocher, A. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03420.x · Cited by 273
Pneumonia Due to Pseudomonas aeruginosa
Fujitani, S., Sun, H.-Y., Yu, V. L., & Weingarten, J. A. (2011) · Chest · doi:10.1378/chest.10-0166 · Cited by 273
Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management
Zhang, C. Y., Gao, J., & Wang, Z. (2018) · Advanced Materials · doi:10.1002/adma.201803618 · Cited by 222
Mobile Carbapenemase Genes in Pseudomonas aeruginosa
Yoon, E.-J., & Jeong, S. H. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.614058 · Cited by 221
Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa
Tomaras, A. P., Crandon, J. L., McPherson, C. J., Banevicius, M. A., Finegan, S. M., Irvine, R. L., Brown, M. F., O'Donnell, J. P., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00629-13 · Cited by 110
Golovkine, G., Faudry, E., Bouillot, S., Voulhoux, R., Attrée, I., & Huber, P. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003939 · Cited by 78
Metadata
- Authors
- El Solh, A. A., & Alhajhusain, A.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-06-11
- Volume
- 64
- Issue
- 2
- Pages
- 229-238
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2129010460
- Cited by
- 172
- References
- 1
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.